ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

South Korean drugmaker Celltrion sets sights on China

Biosimilar specialist also shopping for subsidies to build overseas plant

Led by a former auto industry executive, Celltrion has gone from zero to $840 million in annual sales in 15 years.   © Reuters

SEOUL -- After successfully penetrating the European market, South Korean pharmaceutical company Celltrion has set its sights on a new target: China.

Celltrion is poised to break into the Chinese market as early as 2020 via a joint venture that will allow it to sell biopharmaceuticals in the world's most-populous market.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more